Why the 2023 peptide compounding ban happened: the FDA's rationale

A plain-English read of why several peptides moved to Category 2 — and what the agency actually said.

TL;DR

• In late 2023, the FDA placed BPC-157, TB-500, ipamorelin (briefly), CJC-1295, and others on Category 2, which restricts 503A compounding.
• The rationale was data gaps and unresolved safety questions — not a finding that the peptides were dangerous.
• A February 2026 HHS announcement proposed returning several peptides to Category 1; final status awaits a Federal Register notice.

What it is

The 503A compounding framework (in plain English: the federal rules that let small pharmacies make patient-specific medications) includes a list called the "bulk drug substances used in compounding under section 503A" list. The FDA assigns substances to one of three categories. Category 1 means the substance can be compounded while the agency considers it. Category 2 means it cannot be compounded. The agency cites either significant safety risks or insufficient data to evaluate the substance (FDA bulk drug substances list).

How it works

Think of the framework as a guest list at a restricted club. The Pharmacy Compounding Advisory Committee (PCAC) — a panel of pharmacists, physicians, and consumer representatives — reviews each substance and recommends a category. The FDA can accept or modify those recommendations. When a peptide moves from Category 1 to Category 2, the practical effect is that 503A pharmacies stop compounding it. The compound itself is not banned outright in research — it is removed from the list of substances permitted for pharmacy compounding.

Who asks about it

Patients and clinicians come to this topic when a peptide they were using disappears from a pharmacy formulary. They want to know whether the FDA found something dangerous, whether the decision is permanent, and whether the compound is coming back.

What the research says

The FDA's published rationales for Category 2 decisions cite a few factors. Limited human safety data is one. Manufacturing quality concerns are another. The absence of an approved indication that would justify routine compounding is the third (PCAC meeting materials). For several peptides the agency wrote that "significant safety risks" may exist. For others it cited insufficient data. The distinction matters. Insufficient data is not the same as confirmed harm. Subsequent litigation has argued that decades of animal data should support Category 1 status for several compounds.

What to know before considering it

Category 2 status is not a permanent ban. It is a regulatory line that determines whether 503A pharmacies can compound the substance under current rules. A Federal Register notice — based on PCAC recommendations and FDA review — can move a peptide back to Category 1. Material sold online as "research use only" remains gray-market and is not regulated for human use, regardless of any reclassification news.

The Halftime POV

The honest read of 2023 is that the FDA made a regulatory call with imperfect information, in a category where high-quality human data is genuinely sparse. The 2026 reclassification conversation reflects new information and changed political winds — not a finding that the original decision was wrong. We track Federal Register notices, not headlines.

Related reading:

• Category 1 vs Category 2 peptides: the access framework
• The February 2026 HHS announcement on peptide reclassification
• Why some peptides are still Category 2 after the 2026 reclassification news
• The PCAC advisory committee: what it is and why it matters

---

FAQ

Q: What was the 2023 peptide compounding ban? A: In late 2023, the FDA placed several peptides — including BPC-157, TB-500, ipamorelin (briefly), CJC-1295, and others — on its Category 2 list, which restricts compounding under section 503A. The agency cited safety data gaps and insufficient information on use as a bulk drug substance.

Q: Did the FDA say these peptides were unsafe? A: No. Category 2 status means the FDA flagged unresolved questions, not confirmed harm. The agency wrote that "significant safety risks" may exist or that data was insufficient to evaluate the substance under 503A — different from declaring a compound dangerous.

Q: What does the 2026 reclassification news mean? A: A February 2026 HHS announcement proposed returning several peptides to Category 1 pending formal FDA Federal Register notice. The PCAC advisory committee is expected to discuss specific compounds at its July 2026 meeting. Final status changes through Federal Register publication.

---

Disclaimer

As of 2026-05-13, several peptides discussed in this article — including BPC-157, TB-500, and others — are classified by the FDA as Category 2, which means they are not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.

Get updates

Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.

---

Sources

• FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
• FDA, Pharmacy Compounding Advisory Committee (PCAC) — Meeting Materials

---

This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.